Deep Track Capital, LP Ownership Filing for Aclaris Therapeutics, Inc.

Deep Track Capital, LP, along with its affiliated entities Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has filed a Schedule 13G detailing their beneficial ownership of Aclaris Therapeutics, Inc. common stock. As of March 16, 2026, the reporting persons collectively own 9,345,000 shares, representing 7.01% of the outstanding common stock. This ownership level was determined based on 133,295,189 shares outstanding as of January 30, 2026, and an additional 12.7 million shares sold between March 2 and March 9, 2026. David Kroin, as a control person of Deep Track Capital, LP, is also noted. The filing certifies that the securities were not acquired or held for the purpose of influencing the control of the issuer.